12th Annual FDA/Alzheimer’s Disease Allies Meeting
The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition’s 12th annual meeting will explore the current therapeutic landscape for AD from discovery and validation of novel targets through clinical testing of novel drug candidates and non-pharmacologic interventions.
The meeting will also provide a forum for receiving updates on the National Institutes of Health’s investments in a precision medicine approach to the development of Alzheimer’s disease treatment and prevention. A series of expert presentations will be followed by a robust discussion with the leadership of the National Institute on Aging, CMS, and the FDA’s Division of Neurology Products. These discussions will help to assist the field in more rapidly deploying knowledge to develop and deliver effective pharmacologic and non-pharmacologic therapeutic approaches for AD.
Speakers
Samantha Budd Haeberlein
Biogen
Jinhe Li, Ph.D.
US Green Valley Pharmaceuticals
Suzana Petanceska, Ph.D.
National Institute on Aging
Ben Readhead, MBBS
Arizona State University
Catherine Kaczorowski, Ph.D.
Jackson Labs
Gabriela Chiosis, Ph.D.
Memorial Sloan Kettering Cancer Center
Laurie Ryan, Ph.D.
National Institute on Aging
Laura Baker, Ph.D.
Wake Forest Medical School
Frank Longo, M.D., Ph.D.
PharmatrophiX
Mark Gurney, Ph.D., MBA
Tetra Therapeutics
More Upcoming Events
-
Jan03
13th Annual FDA/ACT-AD Allies Meeting – Common Threads: Learning from the Related Dementias
The Accelerate Cures/Treatments for All Dementias (ACT-AD) Coalition’s 13th virtual annual meeting will explore the…